155 related articles for article (PubMed ID: 38553440)
1. Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab.
McMinn ME; Brister KA; Orr WS; Sheehan NT; Christopher WO
Am Surg; 2024 Mar; ():31348241241642. PubMed ID: 38553440
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab and relatlimab for the treatment of melanoma.
Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract][Full Text] [Related]
4. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL; Reeves DJ
Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab Plus Relatlimab: First Approval.
Paik J
Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
Koseła-Paterczyk H; Rutkowski P
Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
[TBL] [Abstract][Full Text] [Related]
8. Relatlimab-nivolumab: A practical overview for dermatologists.
Mullick N; Nambudiri VE
J Am Acad Dermatol; 2023 Nov; 89(5):1031-1037. PubMed ID: 37343829
[TBL] [Abstract][Full Text] [Related]
9. Abscopal effect observed in visceral and osseous metastases after liver SBRT in combination with nivolumab and relatlimab for sinonasal mucosal melanoma-a case report.
Cerbon D; Moya-Brown K; Mihaylov IB; Spieler B
Front Oncol; 2023; 13():1143335. PubMed ID: 37182135
[TBL] [Abstract][Full Text] [Related]
10. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.
Su J; Fu Y; Cui Z; Abidin Z; Yuan J; Zhang X; Li R; Zhao C
Front Pharmacol; 2023; 14():1349081. PubMed ID: 38269271
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
[TBL] [Abstract][Full Text] [Related]
12. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA
J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788
[TBL] [Abstract][Full Text] [Related]
13. Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
Zhao Y; Hu Z; Bathena SP; Keidel S; Miller-Moslin K; Statkevich P; Bello A; Roy A; Suryawanshi S
Clin Cancer Res; 2024 Jan; ():. PubMed ID: 38295151
[TBL] [Abstract][Full Text] [Related]
14. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
Hegewisch-Becker S; Mendez G; Chao J; Nemecek R; Feeney K; Van Cutsem E; Al-Batran SE; Mansoor W; Maisey N; Pazo Cid R; Burge M; Perez-Callejo D; Hipkin RW; Mukherjee S; Lei M; Tang H; Suryawanshi S; Kelly RJ; Tebbutt NC
J Clin Oncol; 2024 May; ():JCO2301636. PubMed ID: 38723227
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA; Lipson EJ; Dummer R; Larkin J; Long GV; Sanborn RE; Chiarion-Sileni V; Dréno B; Dalle S; Schadendorf D; Callahan MK; Nyakas M; Atkinson V; Gomez-Roca CA; Yamazaki N; Tawbi HA; Sarkis N; Warad D; Dolfi S; Mitra P; Suryawanshi S; Grob JJ
J Clin Oncol; 2023 May; 41(15):2724-2735. PubMed ID: 36780608
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Schuler M; Cuppens K; Plönes T; Wiesweg M; Du Pont B; Hegedus B; Köster J; Mairinger F; Darwiche K; Paschen A; Maes B; Vanbockrijck M; Lähnemann D; Zhao F; Hautzel H; Theegarten D; Hartemink K; Reis H; Baas P; Schramm A; Aigner C
Nat Med; 2024 Apr; ():. PubMed ID: 38689060
[TBL] [Abstract][Full Text] [Related]
17. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
[TBL] [Abstract][Full Text] [Related]
18. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D; Tawbi H; Lipson EJ; Stephen Hodi F; Rutkowski P; Gogas H; Lao CD; Grob JJ; Moshyk A; Lord-Bessen J; Hamilton M; Guo S; Shi L; Keidel S; Long GV
Eur J Cancer; 2023 Jul; 187():164-173. PubMed ID: 37167764
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
Thudium K; Selby M; Zorn JA; Rak G; Wang XT; Bunch RT; Hogan JM; Strop P; Korman AJ
Cancer Immunol Res; 2022 Oct; 10(10):1175-1189. PubMed ID: 35981087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
